“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Wednesday, August 27, 2025

Adamas Pharmaceuticals


Adamas Pharmaceuticals — A to Z Product Catalog

Marketed Products (acquired by Supernus as of late 2021)

  • Gocovri® (amantadine ER capsules)
    • Generic: Amantadine extended-release (bedtime-administered, DR/ER)
    • Indication: Adjunctive therapy for levodopa-induced dyskinesia and OFF episodes in Parkinson’s disease
    • Dose/Form: Capsules at bedtime—commonly a delayed-release/extended-release formulation designed for sustained symptom control the following day

  • Osmolex ER® (amantadine ER tablets)
    • Generic: Amantadine extended-release tablets
    • Indication: Treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adults
    • Dose/Form: Once-daily extended-release oral tablet (strengths per prescribing information)

Investigational Product (prior to acquisition)

  • ADS-5102 (amantadine HCl extended-release capsules)
    • Generic: Amantadine HCl (extended-release, investigational)
    • Indication (studied): Levodopa-induced dyskinesia in Parkinson’s disease (and walking impairment in multiple sclerosis in separate studies)
    • Dose/Form (studied): Titrated—170 mg nightly at bedtime in week 1, followed by 340 mg nightly for up to ~25 weeks; some MS walking-impairment studies also tested 137 mg or 274 mg daily dosing.


on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)